Neumora Therapeutics, a clinical-stage biopharmaceutical company redefining neuroscience drug development, announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora’s executive team, reporting to Henry Gosebruch, president and CEO. “I am excited to welcome…
GenEdit, a developer of genetic medicines that leverage its NanoGalaxy® platform for tissue-selective delivery, announced a multiyear collaboration and license agreement with Genentech, a member of the Roche Group. The companies will employ GenEdit’s NanoGalaxy platform to discover and develop…
Bayer announced that Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals Division, effective April 1, 2024. He will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and President Pharmaceuticals. Ambrogio will…
Sanofi and Inhibrx, a publicly traded clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, have entered into a definitive agreement under which Sanofi has agreed to acquire Inhibrx following the spin-off of non-INBRX-101 assets…
Bristol Myers Squibb announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc.®. With the completion of the acquisition, Mirati shares have ceased trading on the NASDAQ Global Select Market and Mirati is now a wholly owned subsidiary…
Sandoz has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI® (ranibizumab-eqrn) from Coherus BioSciences, for an upfront cash purchase payment of USD 170 million. This agreement is inclusive of a biologics license application, product inventory, ophthalmology sales and…
Abdi Ibrahim Pharmaceuticals, the leader of the Turkish pharmaceutical industry, has made two senior executive appointments in line with its vision for growth in international markets. Barış Güven, who has held senior positions in various international companies for nearly 20…
Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival compared to TACE alone in patients with…
Johnson & Johnson announced that FDA approved a supplemental New Drug Application (sNDA) for BALVERSA® (erdafitinib) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations…
BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced strategic financing from Blue Owl Capital and CPP Investments, through a wholly owned subsidiary of CPPIB Credit Investments Inc., bringing in capital of up to $1.25 billion.…